Inspection Readiness

FDA to Begin Unannounced Inspections of Non-U.S. Manufacturing Facilities

Beginning August 2025, FDA inspections at non-U.S. manufacturing sites will take place without advance notice. This shift eliminates prior warning and signals a new standard for global regulatory oversight—one that demands continuous readiness.

With deep FDA expertise and regulatory professionals positioned around the world, ProPharma helps pharmaceutical, biotechnology, and medical device companies build and sustain inspection readiness—before the FDA arrives.

Inspection Readiness is not an option – now, more than ever, it is urgent.

We ensure that every step towards Inspection Readiness is carefully calibrated to your needs. Our method is backed by tangible tools and training programs developed from the ground up, tailored not just to your product, but to your organization's unique scale and scope. This approach allows you to maintain focus on running your business, while we dedicate ourselves fully to your Inspection Readiness, making it our singular priority.

Contact Us Today

Our team of experts are equipped to guide you through every step of any inspection your firm is facing, with experience and expertise. The overview below outlines how ProPharma supports clients through every stage of the inspection readiness lifecycle.

inspection-readiness-workflow-illustration

 

Inspection Readiness Experts

Unannounced inspections are coming. Preparation can't wait.

With global regulatory and quality expertise and a history of guiding clients through successful FDA inspections, ProPharma helps ensure your operations are always inspection ready—no matter when the FDA arrives.

Secure Your Regulatory Inspection Success

On average a new product takes approximately 10-15 years to develop, whether it is a biologic, a pharmaceutical product, a medical device, or a combination thereof.

  • Can you risk the time and resources you invested in development by ignoring the importance of Inspection Readiness for a new product?
  • Can you risk having an existing product off the market for remediation activities following a For Cause Inspection?
  • Can your patients?

ProPharma's expertise covers all aspects of Inspections. Inspection Readiness Evaluation, Project Management, your Inspection Program/Process, Logistics, and Training – are just some of the most important areas of Inspection Readiness. Our expertise can become your greatest asset. We are eager to become your partner in navigating this critical process.

Group of business professionals working at a conference table with laptops and clipboards
Group of medical professionals smiling in a common area

PAI Readiness

Pre-approval Inspections are one of the most critical inspections any Biologic, Pharmaceutical or Medical Device firm will undertake. Failure to meet FDA expectations can have a huge impact on organizations, including:

  • Delays to product launch.
  • Thousands, if not millions of dollars, in remediation costs.
  • Lost market share.
  • Loss of a firm's credibility.

PAI readiness is critical, and ProPharma is an industry leader in providing PAI Readiness to our clients.

BIMO Readiness

BIMO inspection readiness is essential for sponsors to ensure compliance with FDA regulations, protect data integrity, and uphold patient safety standards. By preparing thoroughly, sponsors:

  • Ensure compliance with FDA regulations.
  • Protect data integrity.
  • Uphold patient safety standards.
  • Help avoid costly delays.
  • Prevent potential compliance issues.
  • Facilitate smoother FDA inspections.
Healthcare provider looking into medical device

To date, we have had a 100% success rate on PAI Readiness projects for our clients

News & Insights

Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Developers

March 17, 2026

Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Develope...

The Supreme Court's review of Hikma v. Amarin could reshape the legal and regulatory landscape for skinny labels and Section viii carve-outs.

Benefits of Site Support

March 16, 2026

Benefits of Site Support

Enhance clinical trial performance with Site Support, offering scalable, specialized assistance to improve recruitment, retention, data quality, and reduce administrative burden for research sites.

Global Medical Information, Local Voices: Multilingual Contact Centers That Scale

March 9, 2026

Global Medical Information, Local Voices: Multilingual Contact Centers That Scal...

Discover how ProPharma's multilingual contact centers deliver consistent, accurate medical information globally, ensuring compliance and cultural alignment with over 35 languages.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

December 4, 2025

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

ProPharma taps Daniel Ryan as President of Clinical Research Solutions, strengthening its clinical trial management leadership and expanding its FSP Solutions.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Flyers CMO Compass & Supply Chain Management - ProPharma

March 16, 2026

CMO Compass & Supply Chain Management

ProPharma provides comprehensive supply chain management and consulting services to support the efficient delivery of clinical trial materials throughout the product lifecycle. Using its CMO Compass®...

Case Study Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partnership - ProPharma

March 13, 2026

Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partne...

A mid-sized biotechnology company operating in the EU faced critical pharmacovigilance (PV) compliance findings following an inspection by the European Medicines Agency and Medicines and Healthcare...

Case Study Setting up a Global PV System - ProPharma

February 5, 2026

Setting up a Global PV System

A company needed to rapidly establish a fully compliant global pharmacovigilance (PV) system, including UK/EU QPPV coverage, to meet regulatory requirements by a fixed deadline. With safety data and...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

March 12, 2026

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

Uncover the intricacies of Pharmacovigilance System Master File (PSMF) management and explore proven strategies to ensure inspection readiness, effective MAH oversight, and regulatory compliance...

News & Insights

Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Developers

March 17, 2026

Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Develope...

The Supreme Court's review of Hikma v. Amarin could reshape the legal and regulatory landscape for skinny labels and Section viii carve-outs.

Benefits of Site Support

March 16, 2026

Benefits of Site Support

Enhance clinical trial performance with Site Support, offering scalable, specialized assistance to improve recruitment, retention, data quality, and reduce administrative burden for research sites.

Global Medical Information, Local Voices: Multilingual Contact Centers That Scale

March 9, 2026

Global Medical Information, Local Voices: Multilingual Contact Centers That Scal...

Discover how ProPharma's multilingual contact centers deliver consistent, accurate medical information globally, ensuring compliance and cultural alignment with over 35 languages.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

December 4, 2025

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

ProPharma taps Daniel Ryan as President of Clinical Research Solutions, strengthening its clinical trial management leadership and expanding its FSP Solutions.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Flyers CMO Compass & Supply Chain Management - ProPharma

March 16, 2026

CMO Compass & Supply Chain Management

ProPharma provides comprehensive supply chain management and consulting services to support the efficient delivery of clinical trial materials throughout the product lifecycle. Using its CMO Compass®...

Case Study Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partnership - ProPharma

March 13, 2026

Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partne...

A mid-sized biotechnology company operating in the EU faced critical pharmacovigilance (PV) compliance findings following an inspection by the European Medicines Agency and Medicines and Healthcare...

Case Study Setting up a Global PV System - ProPharma

February 5, 2026

Setting up a Global PV System

A company needed to rapidly establish a fully compliant global pharmacovigilance (PV) system, including UK/EU QPPV coverage, to meet regulatory requirements by a fixed deadline. With safety data and...

Previous Resource Arrow Next Resource Arrow
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

March 12, 2026

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

Uncover the intricacies of Pharmacovigilance System Master File (PSMF) management and explore proven strategies to ensure inspection readiness, effective MAH oversight, and regulatory compliance...

Previous Webinar Arrow Next Webinar Arrow